InvestorsHub Logo
Followers 48
Posts 3935
Boards Moderated 0
Alias Born 01/26/2011

Re: nuke661 post# 120408

Saturday, 04/27/2013 7:21:45 PM

Saturday, April 27, 2013 7:21:45 PM

Post# of 346136

BUT, what if the sub-group analysis shows complete responses



I think you have the right idea, but wouldn't limit it to one indication. I anticipate we'll see a significant number in remission for the 2nd line NSCLC trial and breast cancer trial at ASCO, too.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News